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In Brief Nguyen et al. show that ERG activates YAP1-regulated transcriptional output and that activation of ERG or YAP1 in mouse prostate induces similar transcriptional changes and age-related prostate tumors. Moreover, pharmacological inhibition of YAP1 suppresses growth of ERG-positive human prostate tumor xenografts.
INTRODUCTION
The development of effective prevention and treatment strategies for prostate cancer requires understanding the critical molecular alterations that drive the initiation of neoplasia and subsequent development of malignant characteristics. The notable finding that recurrent chromosomal recombination events result in ERG oncogene overexpression in prostate cancers provides compelling evidence supporting the hypothesis that ERG, and potentially other ETS family transcription factors, function as key drivers of prostate carcinogenesis (Tomlins et al., 2005) . ETS family gene rearrangements occur in 20%-50% of all human prostate adenocarcinomas, depending on racial background, and are found in precursor lesions and across all histological grades and tumor stages (Sreenath et al., 2011; Tomlins et al., 2005) .
Cause and effect studies of phenotypic changes resulting from high ERG activity have been conducted using a spectrum of cell lines, xenografts, and genetically engineered mouse (GEM) models. Knockdown of ERG in VCaP prostate adenocarcinoma cells, a line that harbors a functional TMPRSS2-ERG rearrangement (Tomlins et al., 2005) substantially reduces cell invasion and attenuates proliferation (Gupta et al., 2010; Tomlins et al., 2008; Wang et al., 2008) . Consistent with lossof-function studies in VCaP cells, overexpression of ERG or other ETS family genes in immortalized prostate epithelial cell lines results in a substantial increase in cell invasion (Klezovitch et al., 2008; Tomlins et al., 2007) . At the molecular level, ERG has been shown to influence androgen receptor signaling, induce a repressive epigenetic program via activation of EZH2, activate Wnt pathway signaling, and promote NFkB-mediated
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Developing therapeutic approaches to inhibit ERG activity is challenged by a paucity of knowledge about the mechanisms responsible for ERG-mediated transformation. We found that ERG activates the transcriptional output regulated by YAP1 and determined that genetic activation of YAP1 in mouse prostate epithelium is sufficient to induce age-dependent prostate neoplasms that are similar to tumors caused by ERG upregulation. These results reveal an important connection between ERG and the Hippo pathway. Moreover, we demonstrate that pharmacological inhibition of YAP1 activity prominently inhibits the orthotopic growth of pre-established ERG-positive human prostate tumors, supporting the development of clinical strategies targeting YAP1 in tumors with ERG rearrangements.
transcription (Chen et al., 2013; Gupta et al., 2010; Wang et al., 2011; Yu et al., 2010) .
To confirm a causal role for ERG in the genesis of prostate cancer, several GEM models have been constructed that express ERG specifically in prostate epithelial cells. These models are notable for a range of relatively subtle phenotypic changes that include the partially penetrant formation of focal precancerous lesions or focal hyperplasia (Baena et al., 2013; Chen et al., 2013; Klezovitch et al., 2008; Tomlins et al., 2008) , or a complete absence of any discernable phenotype (Carver et al., 2009a (Carver et al., , 2009b King et al., 2009) . In contrast to the minimal oncogenic effects observed in ERG transgenic mice, when combined with Tp53 loss or Pten inactivation, ERG promotes invasive and metastatic phenotypes. The differences in ERG-mediated effects between human and mouse cells and between the different GEM models can be potentially explained by the level of transgene expression; however, the relative levels of ERG protein expression in many transgenic models have either not been reported (Carver et al., 2009a (Carver et al., , 2009b King et al., 2009) or found to be low in comparison to levels in human prostate cancer (Baena et al., 2013; Casey et al., 2012) . To better understand the importance of ERG and determine the mechanism(s) by which it can promote neoplasia, we analyzed transgenic mice expressing ERG in prostate epithelium at levels comparable to those found in ERG-rearranged primary human prostate cancers in vivo.
YAP1 is a component of the canonical Hippo signaling pathway that comprises a cascade of kinases that includes the Hippo/ MST1-2 kinases, the adaptor Sav1, and the LATS1/2 kinases. Hippo signaling culminates in the phosphorylation and consequent inactivation of the transcriptional co-activators YAP1 and TAZ by LATS1/2, which suppresses the TEAD-dependent expression of a network of genes that promote cell proliferation and survival. Studies in mouse models have shown that LATS1/ 2 kinases exert tumor suppressive effects and YAP1 functions as an oncogene (Pan, 2010) . Hippo pathway activity is strongly implicated in the pathogenesis of human medulloblastomas, oral squamous-cell carcinomas, and carcinomas of the lung, pancreas, esophagus, liver, and mammary gland (Pan, 2010) . While previous studies have determined that the Hippo kinases MST1/2 and LATS1/2 are downregulated and YAP is upregulated in a subset of primary human prostate cancers (Cinar et al., 2007; Steinhardt et al., 2008; Zhao et al., 2012) , the causes and consequences of YAP1 activation have not been defined, nor have causal roles for Hippo signaling in the genesis of prostate cancer been established.
RESULTS

Age-Dependent Prostate Tumors Develop in Transgenic
Mice Expressing High Levels of ERG To determine the consequences of ERG overexpression in prostate epithelium in vivo, we performed extensive longitudinal analyses of a GEM model, Tg(Pbsn-ERG)1Vv, designed to express high levels of ERG in prostate epithelium (Klezovitch et al., 2008) . This mouse line integrated the transgene in an intergenic region on chromosome 1, expresses ERG at levels comparable to primary human prostate cancers with ERG rearrangements, and displays transcriptional changes that significantly correlate with those identified in ERG + human prostate tumors ( Figure 1A ; Figure S1 ; Tables S1A-S1C). We found that aged Tg(Pbsn-ERG)1Vv mice develop prostate tumors and have a shorter lifespan than wild-type littermates (Figure 1B) . Overall, approximately 50% of Tg(Pbsn-ERG)1Vv transgenic mice aged 2 years and older developed prostate tumors, while none were found in wild-type littermates (Table  1) . This is consistent with a lack of spontaneous prostate cancer in aged wild-type mice (Sharma and Schreiber-Agus, 1999) . The level of ERG transgene expression was important, as we found no prostate tumors in aged mice from a different line Tg(Pbsn-ERG)8Vv (n = 9), which expressed substantially lower levels of ERG ( Figure S1A ).
We observed several prostate tumor phenotypes in aged Tg (Pbsn-ERG) (Figure 2 ). We conclude that the expression of ERG in prostate epithelial cells in vivo, at levels that are clinically relevant, is sufficient to cause the slow and partially penetrant emergence of age-related prostate tumors, a disease course that parallels prostate cancer development in men.
Activation of Hippo Pathway Target Genes in ERG Transgenic Mice
To determine the primary mechanisms responsible for the tumorigenic function of ERG, we analyzed gene expression changes in the prostates of Tg(Pbsn-ERG)1Vv mice prior to tumor development. Analyses of well-established gene targets of the canonical Wnt, Hedgehog, TGFb, Notch, and Hippo signaling pathways revealed epithelium-specific activation of Ctgf, a gene directly regulated by the Hippo pathway transcriptional activator YAP1 ( Figures 3A-3E ). In the canonical Hippo signaling pathway, YAP1 activity is negatively regulated by phosphorylation at S127 by the LATS1/2 kinases, which results in cytoplasmic retention and inactivation of YAP1 (Zhao et al., 2011) . We hypothesized that as yet undefined targets of ERG reduced YAP1 S127 phosphorylation, resulting in elevated YAP1 activity and consequent upregulation of Ctgf. However, we observed no reduction in YAP1 S127 phosphorylation or LATS1/2 inactivation in Tg(Pbsn-ERG)1Vv prostates compared with controls ( Figure 3F ). Moreover, we found that YAP1 was prominently expressed and localized to the nucleus in luminal epithelial cells in both wild-type and ERG transgenic mice (Figures 3G and 3H) . These experiments indicate that the enhanced Ctgf expression in Tg(Pbsn-ERG)1Vv prostates is not due to decreased activity of LATS1/2 of the Hippo signaling pathway, though the findings did not preclude alternative mechanisms leading to the augmentation of YAP1 signaling and consequent Ctgf upregulation.
Overexpression of ERG in Non-tumorigenic Prostate Epithelial Cells Activates YAP1 Target Genes and Increases YAP1-Mediated Transcriptional Output To investigate the role of ERG in regulation of Hippo signaling in prostate epithelial cells in culture using gain-of-function experiments, we engineered RWPE-1 cells to stably express ERG, constitutively active YAP1 (Yap1S127A [Dong et al., 2007] ), or both ERG and YapS127A (Figures 4A-4D ; Figure S2A ). The RWPE-1 cell line is a model of immortalized non-tumorigenic human basal epithelial cells, which do not express endogenous ERG (Bello et al., 1997; Litvinov et al., 2006) . RNA sequencing (RNA-seq) analysis identified a significant overlap between genes upregulated through ERG expression and those regulated through Yap1S127A (p < 0.001; Figures 4A and 4B; Tables S2 and S3) . Similarly, gene set enrichment analysis (GSEA) confirmed prominent similarities between ERG and Yap1S127A transcriptional programs ( Figure 4D ). qRT-PCR analysis not only confirmed ERG-mediated upregulation of the ''Hippo pathway down'' signature genes CTGF and ENC1 (Mohseni et al., 2014) but also demonstrated that ERG was able to increase their expression levels even in cells expressing constitutively active Yap1S127A, which cannot be inactivated by phosphorylation See also Figure S1 and Table S1. at S127 by LATS1/2 ( Figure 4C ). Moreover, analyses of YAP1 S127 phosphorylation and the Hippo pathway kinases, MST1 and LATS1, demonstrated that ERG does not significantly impact their levels or activity (Figures S2A and S2B) .
The actin cytoskeleton can in some cases regulate YAP1 activity independently from the Hippo/LATS phosphorylation cascade (Dupont et al., 2011) . As expected, disruption of the actin cytoskeleton prominently downregulated expression of CTGF in RWPE-1 cells; however, this did not erase or decrease the differences in CTGF expression levels between the control and ERG expressing cells, indicating that ERG does not influence YAP1 activity via the actin cytoskeleton ( Figures S2C-S2E ).
YAP1/TAZ Are Necessary for ERG-Mediated Transformation and Invasion of Non-tumorigenic Prostate Epithelial Cells
We next analyzed the functional importance of YAP1/TAZ in mediating ERG-associated malignant phenotypes in RWPE-1 cells. The recently developed 3D organoid prostate culture system faithfully recapitulates the in vivo phenotypes and enables mechanistic studies of prostate development, homeostasis, and cancer (Karthaus et al., 2014) . We found that overexpression of ERG significantly promotes growth of RWPE-1 cells (RWPE-ERG) in the 3D organoid prostate culture system (Figures 4E and 4F) . Importantly, YAP1/TAZ were necessary for this ERGmediated transforming phenotype, because the knockdown of YAP1 and TAZ using two independent sets of small interfering RNA (siRNA) oligos erased the growth differences between RWPE-Crtl and RWPE-ERG cells ( Figures 4G and 4H) . Similarly, the stable knockdown of YAP1 using two independent lentiviral small hairpin RNA (shRNA) constructs also erased the growth differences between RWPE-Ctrl and RWPE-ERG cells in this culture system (Figures S2F and S2G) . We also found that gain of function of YAP1 (YAP1S127A) was sufficient for stimulation of growth of RWPE-1 (RWPE-YAP1) cells in the 3D organoid prostate culture system ( Figure 4I ). Moreover, ERG and YAP1 prominently cooperated with each other in stimulation of growth of RWPE-1 (RWPE-ERG+YAP1) cells in this culture system (Figure 4I) . These data indicate that YAP1/TAZ were both necessary and sufficient for ERG-mediated transformation of RWPE-1 cells. In addition to promoting the growth of RWPE-1 cells in the 3D organoid prostate culture system, overexpression of ERG prominently stimulated formation of RWPE-1 cell colonies in soft agar assays in media containing 1% fetal bovine serum ( Figure S2H ). The stable knockdown of YAP1 using two independent shRNA constructs erased the differences between RWPECrtl and RWPE-ERG cells, confirming that YAP1 was necessary for ERG-mediated transformation of RWPE-1 cells ( Figure S2H ).
ERG has been shown to promote the invasive behavior of human prostate epithelial cells (Brenner et al., 2011; Klezovitch et al., 2008; Tomlins et al., 2008) . Interestingly, constitutively active YAP1 also promotes EMT and cell invasion across a spectrum of tumor types (Lamar et al., 2012; Overholtzer et al., 2006) . Therefore, we asked whether ERG utilizes YAP1/TAZ in the development of this phenotype. As expected, overexpression of ERG promoted matrigel invasion of RWPE-1 (RWPE-ERG) cells ( Figure S2I ). Importantly, knockdown of YAP1 and TAZ erased the differences in invasion between RWPE-Ctrl and RWPE-ERG cells, indicating that YAP1/TAZ are necessary for ERG-mediated stimulation of cell invasion ( Figure S2I ).
ERG Interacts with TEAD-Occupied Chromatin Regions, Increases Histone Acetylation, and Promotes YAP1-Dependent Transcription Since ERG and YAP1 both localize to the nucleus ( Figures 1L,  3G , and 3H), we hypothesized that ERG directly binds and activates YAP1 target genes. YAP1 associates with several distinct transcription factors, though members of the TEAD family are most directly responsible for the proto-oncogenic function of YAP1 (Liu-Chittenden et al., 2012; Zhao et al., 2008) . Chromatin immunoprecipitation sequencing (ChIP-seq) experiments with RWPE-Ctrl and RWPE-ERG cells identified a highly significant overlap between TEAD4 and ERG peaks in RWPE-ERG cells with closely positioned ERG-TEAD4 recognition motifs ( Figures  4J-4L ). Of overlapping ERG-TEAD4 peaks in RWPE-ERG cells, 75% were already occupied by TEAD4 in control RWPE-Ctrl cells, indicating that ERG does not function as a pioneering factor for TEAD4 chromatin binding. Analyses of potential changes in histone modifications in shared ERG-TEAD4 peaks at the promoters of Hippo gene targets, CTGF and ENC1, revealed an ERG-dependent increase in H3K9/14 acetylation, a chromatin mark highly localized to the 5 0 regions of transcriptionally active human genes (Liang et al., 2004) (Figure 4M ).
To determine whether ERG acts directly on the promoters of Hippo target genes, we performed luciferase assays with a CTGF promoter. ERG significantly increased YAP1/TEAD4-mediated CTGF transcription, and both ERG-binding motifs in the CTGF promoter and ERG's ability to bind to DNA were required for this transcriptional activation ( Figures S2J-S2L ). Overall, we conclude that in prostate epithelial cells ERG binds to many TEAD-interacting regions of chromatin, increases the histone H3K9/14 acetylation, and promotes the transcriptional activity of YAP1 target genes.
ERG Maintains YAP1 Expression in Neoplastic Luminal
Prostate Epithelial Cells by Controlling H3K9/14 Acetylation of the YAP1 Promoter To complement the gain-of-function studies, we evaluated the effects of suppressing ERG and YAP1/TAZ activity in a human luminal epithelial line, VCaP, that endogenously expresses high ERG levels by virtue of a TMPRSS2-ERG rearrangement (Tomlins et al., 2005) . RNA-seq analysis of VCaP with siRNAs targeting ERG or YAP1 identified a highly significant overlap between genes altered by loss of ERG and those altered by loss of YAP1/ TAZ activity (p < 0.001; Figures 5A-5D ; Tables S4 and S5) . ChIPseq analysis of ERG and TEAD4 chromatin-binding sites confirmed a highly significant overlap between ERG and TEAD4 peaks in VCaP cells, with closely positioned ERG-TEAD4 recognition motifs ( Figures 5E and 5F ).
Of interest, we found that suppressing endogenous ERG in VCaP cells by siRNAs significantly decreased the expression of endogenous YAP1, as determined by RNA-seq, qRT-PCR, and western blot ( Figure 5D ; Figure S3A ; Table S4 ). We found that both ERG and TEAD4 peaks were present at the transcriptional start site of YAP1, and ChIP-re-ChIP experiments revealed the co-occupancy of ERG and TEAD4 at the YAP1 promoter (Figure 5G ; Figure S3B ). Quantitative ChIP analyses demonstrated substantial downregulation of H3K9/14 acetylation at YAP1 and ENC1 promoters in siERG VCaP cells ( Figure 5H ; Figures  S3C and S3D ). These findings support a direct role for ERG in the maintenance of YAP1 expression in human luminal VCaP cells by controlling H3K9/14 acetylation of the YAP1 promoter.
ERG and YAP1 Are Co-expressed in a Subset of Primary Human Prostate Cancers and YAP1 Associates with Adverse Outcomes To assess the relationships between ERG and YAP1 in human prostate cancer, we performed immunostaining of tissue microarrays (TMAs) with anti-ERG and anti-YAP1 antibodies. Surprisingly, in contrast to the mouse prostate, YAP1 was expressed in the basal, but not in luminal, epithelial cells in normal human prostate glands ( Figure 5I ; Figures S3E and S3F ). Significantly, in human luminal-type prostate carcinomas, YAP1 protein was expressed in 55% (64 of 116) of the tumors evaluated ( Figure 5I ). In the analyzed cohort, 44% (52 of 116) of the cancers also exhibited high ERG expression and there was a highly significant overlap between those primary tumors expressing ERG and those expressing YAP1 (p = 0.0002) ( Figure 5I ). Further, the expression of nuclear YAP1 in primary tumors was significantly associated with tumor recurrence after primary treatment (p = 0.0002) ( Figure S3F ). We conclude that increased YAP1 expression in transformed luminal epithelium may be an important consequence of ERG activity in human prostate cancers.
YAP1 Is Necessary for ERG-Mediated Transformation and Invasion of ERG-Positive Human Prostate Cancer Cells
We next analyzed the functional importance of YAP1/TAZ in mediating ERG-associated malignant phenotypes in VCaP cells. Knockdown of ERG or YAP1/TAZ decreased the invasion of VCaP cells ( Figure S4A ). In addition, suppression of YAP1/ TAZ in VCaP cells also decreased their anchorage-dependent and -independent growth ( Figures S4B-S4D ). Since ERG is necessary for the maintenance of YAP1 expression in VCaP cells, we analyzed whether restoration of YAP1 rescues phenotypes resulting from ERG suppression. Indeed, re-expression of YAP1 completely rescued the invasion and cell growth phenotypes in VCaP cells transduced with shRNAs targeting ERG ( Figures S4E-S4G ). shERG-mediated decrease in the soft-agar colony formation and orthotopic xenograft growth of VCaP cells were significantly, but partially, rescued by re-expression of exogenous YAP1, suggesting that the direct control of YAP1 gene expression can account for many, but not all, cancer relevant phenotypes of ERG in VCaP cells ( Figures S4H-S4J ).
The YAP1 Inhibitor Verteporfin Suppresses ERG-Positive Prostate Carcinoma Growth In Vivo
The in vitro studies indicated that YAP1 is responsible for a significant part of oncogenic programs activated by ERG in prostate cancer. To evaluate the in vivo effects of suppressing YAP1 in the context of ERG-driven cancer, we evaluated a small molecule FDAapproved drug Verteporfin, which was recently identified as a specific inhibitor of YAP1 (Liu-Chittenden et al., 2012) . We found that the systemic administration of Verteporfin substantially inhibited the growth of pre-established orthotopic ERG-positive VCaP xenografts in vivo ( Figures 6A-6D ). In contrast, Verteporfin treatment did not have a statistically significant impact on the growth of pre-established orthotopic ERG-negative PC3 xenografts ( Figures 6E-6H ). As the direct activity of ERG and other transcription factors are challenging to inhibit in vivo, the suppression of YAP1 by Verteporfin may have clinical utility in treating prostate cancers with ERG rearrangements.
Genetic Activation of YAP1 in Mouse Prostate
Epithelium Results in Age-Dependent Development of Prostate Tumors While ERG expression in prostate epithelial cells promotes a YAP1-mediated transcriptional program, the causal effects of activating this program in the context of prostate neoplasia in vivo are not known. To address this question, we utilized transgenic mice carrying a doxycycline (Dox)-inducible allele of constitutively active YAP1 (Yap1S127A) (Camargo et al., 2007) . Prostate epithelium-specific Cre mice (Pbsn-Cre4 [Wu et al., 2001] ) were utilized for Cre-mediated activation of Dox-dependent transactivator (rtTA) (Figures 7A and 7B) . At 3 months of age, we exposed these Pbsn-Cre4/Rosa26-LSL-rtTA/TetOP-YAP1S127A (YAP1-GOF) mice to Dox-containing feed and examined their prostate glands at different time intervals thereafter. We found that similar to the prostate-specific ERG transgenic mice, young YAP1-GOF animals presented with minimal phenotypes, while aged YAP1-GOF animals developed prostate tumors with incidence rates and histological phenotypes similar to the prostate gland tumors in Tg(Pbsn-ERG)1Vv mice ( Figures 7C-7J ). These data demonstrate that activation of a YAP1 transcriptional program in mouse prostate epithelium in vivo results in the development of partially penetrant agerelated prostate tumors. Further, RNA-seq analysis of prostate glands from YAP1-GOF mice revealed that transcriptional changes induced by YAP1 activation in prostate epithelium in vivo significantly overlapped with the transcriptional program activated by prostate epithelium-specific expression of ERG (Figures S5A-S5C; Tables S6, S7 , and S8). Importantly, analyses of human prostate cancer datasets revealed a highly significant overlap between the murine prostate-gland specific YAP1-GOF gene signature and human ERG-positive prostate carcinomas ( Figures S5D-S5F ).
DISCUSSION
Chromosome rearrangements driving high levels of ERG expression occur frequently in prostate cancers, an observation that strongly implicates ETS family oncogenes as major contributors to the genesis and potentially the progression of this disease. However, GEM strategies that have been quite useful in confirming cause and effect relationships for numerous other oncogenes and tumor suppressor pathways have not identified clear mechanisms by which ERG contributes to prostate neoplasia. To date, the reported phenotypes resulting from engineered ERG expression in the mouse prostate have been quite modest (Baena et 2013; King et al., 2009; Klezovitch et al., 2008; Tomlins et al., 2008) . One possibility for the lack of oncogenic activity hinges on the level of ERG expression. Dependence of a phenotype on the level of proto-oncogene expression is frequently seen in transgenic animals (Smith et al., 2006) . The synthetic probasin promoter that confers prostate epithelial specificity provides relatively weak levels of prostate-specific ERG expression. For example, while we generated 14 Tg(Pbsn-ERG) founder lines, only two lines with highest levels of ERG expression display phenotypic changes and only the line with the highest level of ERG expression, which achieves levels seen in human prostate cancers with ERG rearrangements, develops overt tumors in the prostate gland.
A second consideration regarding prostate cancer phenotypes concerns the age-related dependency of prostate neoplasms. Human prostate cancer is highly associated with advanced age and is very infrequently diagnosed in men under the age of 50. Mice do not develop spontaneous prostate (M) qPCR analysis of ChIP experiments from RWPE-Ctrl and RWPE-ERG cells using indicated antibodies. Data represent mean ± SD (n = 4) from one of three independent experiments. Student's t test was used to determine statistical significance. See also Figure S2 and Tables S2 and S3. cancer during their normal lifespan (Sharma and SchreiberAgus, 1999) . Thus, models that accurately reflect disease pathogenesis may exhibit long periods of latency. Consistent with these observations, the prostate tumors that developed in Tg(Pbsn-ERG)1Vv mice generally occurred between 2 and 3 years of age and were focal, involving subsets of epithelial cells with transgene expression. Therefore, even high levels of ERG in mouse luminal prostate epithelial cells are not sufficient to drive the rapid and consistent development of carcinomas, indicating that in addition to ERG expression other genetic or epigenetic changes must occur for frank tumor initiation.
A substantial proportion of the prostate tumors that developed in aged Tg(Pbsn-ERG)1Vv mice are either stromal tumors, which do not express epithelial cell markers, or sarcomatoid carcinomas expressing both epithelial and stromal cell markers. Since we did not detect ERG transgene expression in the prostate stromal cell compartment of Tg(Pbsn-ERG)1Vv mice (Klezovitch et al., 2008) , the origin of the stromal tumors in these aged mice is not clear. Tumors expressing mesenchymal cell markers may originate either in stromal cells expressing very low levels of a transgene or in epithelial cells, which then undergo a prominent EMT and lose markers of epithelial differentiation. The presence of sarcomatoid carcinomas expressing both epithelial and stromal cell markers may represent an intermediate EMT phenotype. While sarcomatoid carcinoma is rarely seen in human prostate cancer, these tumors have epithelial origin (Rodrigues et al., 2015) . Further, mouse prostate epithelial cells readily undergo EMT and present with sarcomatoid carcinomas, which is seen in mice with deletions of Tp53, or the activation of K-Ras or COUP-TFII in prostate epithelium (Martin et al., 2011; Mulholland et al., 2012; Qin et al., 2013; Vinall et al., 2012) .
The generation of a GEM model that recapitulates the levels of ERG found in human prostate epithelium made it possible to (H) qPCR analysis of ChIP experiments from siCtrl, siERG-1, or siERG-2 oligo transfected VCaP cells using indicated antibodies. Data represent mean ± SD (n = 4) from one of three independent experiments. Student's t test was used to determine statistical significance. (I) Significant correlation between ERG expression and presence of nuclear YAP1 in primary human prostate tumors. Immunohistochemical (IHC) staining of prostate cancers (PC1 and PC2) was performed with ERG and YAP1 antibodies. Note that YAP1 is strongly expressed in benign basal but not benign luminal epithelial cells (arrows), but it is present in neoplastic luminal cells in a subset of human prostate carcinomas. The star indicates a histologically benign prostatic gland. The scale bar represents 50 mm. See also Figure S3 and Tables S4 and S5. establish a connection between ERG and the transcriptional output of the Hippo signaling pathway, which is controlled by YAP1/TAZ transcriptional co-activators. We identified two mechanisms by which ERG regulates Hippo pathway signaling ( Figure 7K ). First, we found that in prostate epithelial cells ERG binds to TEAD-occupied regions of chromatin, increases histone acetylation at these sites, and amplifies the transcriptional output controlled by YAP1/TEAD. We also determined that ERG binds to the YAP1 promoter and is required for YAP1 expression in VCaP human luminal prostate cancer cells, identifying a second mechanism directly connecting ERG and YAP1-dependent regulation of transcription. This second mechanism is not apparent in mouse prostate epithelium and in basal-type human prostate epithelial cells, which both already express ample levels of endogenous YAP1. However, it is readily detectable in human luminal-type prostate epithelial cells, which do not express YAP1 under normal conditions and require high levels of ERG to drive YAP1 expression.
Mice with prostate epithelium-specific activation of YAP1 develop phenotypes that are remarkably similar to those observed in Tg(Pbsn-ERG)1Vv mice, suggesting that the activation of YAP1-mediated transcriptional output is an important part of ERG function in the prostate gland. While activation of YAP1 in a variety of mouse organ systems causes dramatic stimulation of cell proliferation and growth, mouse prostate is resistant to YAP1-mediated transformation, with focal tumors appearing only in aged individuals. We found that unlike in human prostate epithelium, endogenous nuclear YAP1 is abundantly present in mouse luminal prostate epithelial cells, thus potentially making the mouse prostate resistant to both ERG and YAP1-mediated transformations, since an additional increase in YAP1-mediated transcriptional output is unlikely to have a profound physiological impact in this environment.
The finding that ERG and YAP1 are concordantly expressed in a subset of human prostate cancers provides support for the clinical relevance of the molecular interactions between these pathways. The tumors expressing YAP1 generally exhibit an unfavorable disease course, and consequently, YAP1 may serve as a marker of aggressive disease. It is not clear why certain tumors with high ERG levels did not express YAP1, though it is notable that none of such tumors analyzed in our study recurred after treatment. Though ERG is an attractive candidate for therapeutics due to the very high prevalence of ERG rearrangements in prostate cancers, in the past it has been challenging to develop agents capable of disrupting the activity of transcription factors. As YAP1 appears to regulate critical components of ERG-mediated neoplasia, inhibiting YAP1 is an attractive alternative. Our preclinical studies demonstrating substantial reductions in the growth of ERG-expressing prostate cancer by the FDAapproved YAP1 antagonist Verteporfin indicate that malignant phenotypes stemming from ERG activity can be suppressed by targeting YAP1, a finding that opens a more straightforward path for drug development and clinical applications.
EXPERIMENTAL PROCEDURES Mice
All animal experiments were done in accordance with protocols approved by the Institutional Animal Care and Use Committees of Fred Hutchinson Cancer Research Center and followed NIH guidelines for animal welfare. Tg(Pbsn-ERG)1Vv mice (Klezovitch et al., 2008) on 129S1/SvlmJ genetic background were aged and analyzed at morbidity with wild-type littermates used as controls. For the generation of prostate-specific YAP1-GOF mice, double heterozygous Col1a1 (Camargo et al., 2007) and Gt(ROSA)26Sor tm1(rtTA,EGFP)Nagy (Belteki et al., 2005) as controls. YAP1 GOF and control animals were switched to Doxycyclinecontaining food (www.bio-serv.com, #S3888) at 3 months of age and maintained on this diet until euthanasia. All animals were analyzed as heterozygous (knock-in) or hemizygous (transgene) mutants.
Mouse Prostate Gland Histo-pathology
The histological assessment of prostate tumors in Tg(Pbsn-ERG)1Vv mice was the result of online discussions with the Pathology Panel of NCI Mouse Models of Human Cancer Consortium (MMHCC) Prostate Cancer on July 2, 2012, chaired by Prof. Robert D. Cardiff (UC Davis). Prostate gland pathology of YAP1-GOF mice was analyzed by Dr. Maria S. Tretiakova (a board-certified pathologist with significant experience with the pathology of the prostate gland).
Gene Expression Analyses
Total RNA was extracted with TRIzol (Invitrogen) followed by RNase-free DNAase treatment (QIAGEN) and an RNeasy RNA purification kit (QIAGEN). Complementary DNA was prepared with a SuperScript III First-Strand Synthesis kit (Invitrogen). qPCR was performed with Prism 7900HT (Applied Biosystems), platinum qPCR mix (Invitrogen), and a Universal ProbeLibrary kit using the primers, probes, and PCR conditions recommended by the Universal ProbeLibrary assay center (http://lifescience.roche.com/shop/ products/universal-probelibrary-system-assay-design). qPCR data were normalized to ribosomal protein Rps16. RNA-seq experiments on RNA from RWPE-1 cells were performed by Beijing Genomics Institute (BGI). The total RNA samples were treated with DNase I, and the mRNA was enriched by using the oligo(dT) magnetic beads, fragmented and used for cDNA synthesis. The library products were sequenced via Illumina HiSeq 2000. The primary reads were mapped using Tophat2 , and differential gene expression was analyzed using EdgeR Bioconductor software. RNA-seq experiments on RNA from VCaP cells and mouse ventral prostate glands were performed using an Encore Complete RNA-Seq Library Systems kit and the Illumina HiSeq 2500 system. The primary reads were mapped using Tophat2 , and differential gene expression was analyzed using CuffDiff (Trapnell et al., 2010) in Galaxy (Blankenberg et al., 2010) . In situ hybridization was performed on frozen sections as described previously (Klezovitch et al., 2004) Human Prostate Tumor TMAs Staining and Analysis Informed consent was obtained from all human subjects, and work was performed in accordance with institutional review board (IRB) approval Numbers denote mice with indicated tumors relative to the number of mice analyzed. The prostate glands were analyzed in mice euthanized at morbidity. The Dox exposure was started at 3 months of age and varied between 12 and 16 months. Two-tailed Fisher's exact test was used to determine statistical significance. (K) Model showing the role of ERG and YAP1 in prostate cancer development. ERE, ERG response element; TRE, TEAD response element. See also Figure S5 and Tables S6, S7 , and S8.
(University of Washington IRB number 39053 and Fred Hutchinson IRB number 460). 127 specimens were obtained from radical prostatectomies performed at the University of Washington, including non-recurrent (n = 64) and recurrent prostate cancer (n = 63). TMAs were made with duplicate cores (1 mm) from paraffin embedded tissues. 4-micron TMA sections were deparaffinized, re-hydrated, rinsed, and blocked for endogenous peroxidase on the automated immunostainer (Bond III, Leica Biosystems) using manufacturer recommended protocols and solutions. Then slides were incubated for 15 min with rabbit monoclonal ERG-antibody (Epitomics, clone EP111, 1:400) or rabbit polyclonal anti-YAP1 (Santa Cruz, #sc-15407, 1:100). This step was followed by 8 min with anti-rabbit Poly-HRP-IgG polymer detection reagent (Leica Biosystems), visualization with 3,3''-Diaminobenzidine chromogen, and counterstaining with hematoxylin. The TMA cores were scored by the pathologist (M.T.) blind to cancer outcomes. The tumors displaying positivity in >10% tumor nuclei were defined as either ERG-positive or YAP1-positive.
Statistical Analyses
Statistical significance was determined by Student's, Fisher's exact, MannWhitney, or Chi-square tests. p value is indicated by asterisks in the figures: *p < 0.05; **p < 0.01; ***p < 0.001. Differences at p = 0.05 and lower were considered statistically significant. In RNA-seq and ChIP-seq analyses, the differences with q < 0.05 were considered statistically significant.
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